P.KlukinE.BoumaizaM.SrivastavaA
Beyond glycemic effects, GLP-1 receptor agonists slow gastric emptying, which prolongs the sensation of fullness after meals and contributes to reduced caloric intake
Over recent decades, our knowledge of eryptosis has been significantly expanded, providing more insights into the uniqueness of cell death pathways in erythrocytes

GLP-1 receptor agonists are licensed in the UK for type 2 diabetes and weight management, including semaglutide, dulaglutide, and liraglutide These medications reduce HbA1c by approximately 1.01.5 percentage points and improve both fasting and post-meal glucose levels Weight loss associated with GLP-1 therapy can lead to secondary improvements in insulin resistance, particularly through reduction of visceral fat Common side effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhoea, which typically diminish over several weeks NICE recommends continuation only if patients achieve at least 1.0 percentage point HbA1c reduction within six months of treatment initiation Patients with diabetic retinopathy require close monitoring, and GLP-1 medications should be discontinued at least two months before planned pregnancy Table of Contents What Are GLP-1 Receptor Agonists and How Do They Work
Optimal Timing: Take them on an empty stomach